- BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares jump after the FDA approved supplemental marketing application seeking approval for RAPIVAB (peramivir injection) to treat acute uncomplicated influenza to include patients six months and older who have been symptomatic for no more than two days.
- Before this approval, RAPIVAB had been indicated for patients two years and older.
- BCRX shares gained 7.03% at $11.27 pre-market on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
